Apyx Medical Reports Strong Q4 2025 Results, Beats EPS Estimates, and Projects Continued Growth for 2026
APYX has more than doubled off its 52-week low of $0.755 on elevated volume (1.9× avg).
Summary
Apyx Medical Corporation reported record Q4 2025 revenue and a significant reduction in net loss, beating analyst EPS estimates and achieving positive Adjusted EBITDA for the quarter. The company also provided optimistic revenue guidance for fiscal year 2026, driven by strong demand for its AYON Body Contouring System.
Key Events · Earnings and Guidance · APYX
-
Strong Q4 2025 Financial Performance
Reported record total revenue of $19.2 million for the fourth quarter of 2025, a 34.7% increase year-over-year, and significantly reduced net loss to $1.3 million.
-
EPS Beat Analyst Estimates
Achieved a net loss of $0.03 per share for Q4 2025, outperforming analyst projections of a $0.06 loss per share.
-
Positive Adjusted EBITDA
Turned around to positive Adjusted EBITDA of $0.7 million in Q4 2025, compared to a $2.2 million loss in the prior year period.
-
Robust Surgical Aesthetics Growth
Surgical Aesthetics revenue grew 38.1% in Q4 2025, primarily driven by strong U.S. demand for the newly launched AYON Body Contouring System.
Analysis · APYX · Industrial Applications And Services
Apyx Medical's Q4 2025 earnings report signals a positive operational turnaround, with the company achieving record revenue and significantly narrowing its net loss, while also reaching positive Adjusted EBITDA for the quarter. The reported loss per share of $0.03 was notably better than analyst expectations of a $0.06 loss, indicating stronger-than-anticipated performance. The robust 38.1% growth in the Surgical Aesthetics segment, fueled by the successful U.S. launch of the AYON Body Contouring System, is a key driver of this momentum. The company's guidance for continued revenue growth in 2026, alongside a projected decrease in OEM revenue as it focuses on its core surgical aesthetics, suggests a strategic shift towards higher-margin products. Investors should monitor the continued scaling of the AYON system and the anticipated FDA clearance for label expansion in mid-2026, as these factors are crucial for sustaining growth and achieving profitability.
At the time of this filing, APYX was trading at $3.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $140.7M. The 52-week trading range was $0.76 to $4.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.